Meningococcal Vaccine Market Size, Share, By Vaccine Type (Conjugative, Polysaccharide, and Others), Serotype (Serotype A, Serotype B, Serotype C, Serotype W, and Serotype Y), Age Group (Infants, Children and Adults), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Healthcare Institutions, and Others) and Region - Trends, Analysis, and Forecast till 2035

• The Meningococcal Vaccine Market size is expected to grow at a valuation rate of USD 6.1 Billion, by 2035.
• In 2024, the market for meningococcal vaccine market valuation was worth USD 3.3 Billion.
• The market is growing at a CAGR of 6.3%.  

Meningococcal vaccine is a type of vaccine that protects against infectious used by Neisseria meningitides, a bacterium that can lead to serious illness such as meningitis and septicemia. There are major two type of meningococcal vaccine, is Meningococcal conjugate vaccines (MenACWY), which protects against serotype A, C, W, & Y, the one is, Meningococcal B vaccine (MenB), which protects against serotype B.

Many government and global health organization such as WHO are introducing new vaccines against meningitis and septicemia to distribute vaccines in low & middle income countries, is anticipated to drive target market growth. Technological advancement in new vaccine technologies, and approval to new vaccines from regulatory bodies is projected to growth of meningococcal vaccine market share.

Increasing awareness of meningococcal diseases, rising global healthcare spending, and advancement in vaccine technology is estimated to fuel expansion of meningococcal vaccine market size. The increasing demand for meningococcal vaccines for travelers, high-risk population, introduction of combination vaccines, and increasing focus on preventive healthcare, is expected to boost meningococcal vaccine market size.

Impact of Generative AI on Meningococcal Vaccine Market:

Artificial Intelligence (AI) can analyze vast amounts of biological, clinical, and genomic data, and help to identify new vaccine optimization with more efficiently. AI can help in personalized vaccines by analyzing individual genetic makeup, lifestyle, and medical history, to tailored immunization strategies for individuals or group of peoples. AI powered models can monitor adverse effects in real-time by analyzing large datasets from healthcare providers, health reports, which allows for rapid response of safety concerns.

Key Drivers of Target Market:

Introduction to New Vaccines against Meningitis can assist to Market Growth

The development of innovative vaccines, which provide protection against five strains of the meningococcus bacteria such as A, C, W, Y, and X. New vaccines aim to improve efficacy and safety profiles of patient and encourage more individuals to get vaccinated which have significant impact on the growth of meningococcal vaccine market. The public health organization such as, WHO, GAVI, and national governments, are help to introduce new vaccines with advanced techniques can boost the demand for new vaccines. The rising awareness about preventive healthcare, increases the demand for protection against preventive diseases, resulting to drive meningococcal vaccine market growth.

• For instance, according to article published by World Health Organization (WHO) in October 2023, this article states that, introduction of the Men5CV vaccine  is a major advance in the global fight against meningitis, particularly in the meningitis belt of sub-Saharan Africa. This vaccine was significantly improve the prevention and control of bacterial meningitis in regions that have long struggled with high incidence rates and limited access to existing vaccines. Men5CV is designed to provide protection against multiple strains of meningococcal bacteria that cause the disease. It offers coverage against serogroups A, C, W, X, and Y, the primary serogroups responsible for meningococcal disease in the meningitis belt. In September 2023, the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommended that all countries in the meningitis belt introduce Men5CV into their routine vaccination programs.

Restraints:

Complex Manufacturing and Supply Chain Challenges Limits Growth of Target Market

Meningococcal vaccine production involves antigen purification, formulation and ensuring vaccine effectively targets multiple serogroups, which required specialized expertise and advanced technologies. Vaccine production depends on a global supply chain for raw materials, components and equipment. Disruption in supply chain such as shortages of essential materials, global crises can delay vaccine producing, resulting to disturb meningococcal vaccine market growth.

• Counterbalance Statements: Advances in bio manufacturing technologies such as mRNA technology and lyophilization, can continuous manufacturing methods and improve logistics, this can help to improve production process, and reduce manufacturing costs. Improve manufacturing techniques to reduce costs, and adoption of block chain technologies for tracking vaccines can reduce the risk of distributions.

Opportunities & Market Trends:

 Rising Approval for Meningococcal Vaccine for Better Serotype Protection Fuels Market Expansion

Tradition vaccine can only target a limited number of meningococcal serogroup, thus the development of new vaccines can protect against multiple serotypes and strains of Neisseria meningitides. The regulatory agencies such as U.S. FDA, European Medicines Agency (EMA) and WHO Prequalification Program, are rapidly approving vaccines with multiple serotype protection. The faster approval of meningococcal vaccines can extend serotype protection, particularly in rural areas, which contributes to meningococcal vaccine market growth.

The meningococcal vaccine market is segmented into vaccine type, serotype, age group, distribution channel, and region.

By Vaccine Type:

Based on vaccine type, meningococcal vaccine are classified into conjugative, polysaccharide, and others. Conjugative segment dominates in target market due to their high efficacy, and ability to offer long-term protection. Conjugative vaccines offer superior response in infants and children, which is widely used in both routine and emergency vaccination programs, resulting to drive meningococcal vaccine market growth.

Polysaccharide vaccine segment hold the second largest meningococcal vaccine market share. It is primarily used in older individuals, high-risk group, such as military, personal, travelers to prevent high-risk, is anticipated to drive target market growth.

By Serotype:

By Serotype, meningococcal vaccine market is divided into Serotype A, Serotype B, Serotype C, Serotype W, and Serotype Y. Serotype B segment dominates in target market due to high prevalence of serotype B in developed region. Serotype B is most prevalence in adolescents and young adults, increasing awareness about global health initiatives which focusing on reducing the impact of serotype B diseases is anticipated to drive segment’s growth in meningococcal vaccine market.

Serotype A is the second dominating segment in meningococcal vaccine. The target market growth is driven by, growing demand for MenA vaccines in low-middle income countries, and it is first preferred by WHO and Gavi for helping to curb outbreaks in the African meningitis belt.

By Age Group:

On the basis of age group, meningococcal vaccine market is segmented into infants, children & adults. Children and adults segment dominates in target market due to meningococcal disease is prevalent in children, adolescents, and young adults, making them the primary targets for vaccination programs. Children and adults have the higher risk of meningitis and septicemia, as the result many vaccination programs are largely focused on the se age groups to reduce incidence of disease, resulting to segment’s growth in meningococcal vaccine market size.  

Infants is growing segment in target market. The vaccines used for infants are MenC or MenACWY conjugate vaccines, as these offer protection from the most prevalent strains of the bacteria. Vaccination at a younger age is intended to prevent early exposure to meningococcal diseases, and in some areas, infants receive vaccines as part of national immunization schedules, is expected to propel growth of meningococcal vaccine market size.

By Distribution Channel:

By distribution channel meningococcal vaccine market is segmented into, hospital pharmacies, retail pharmacies, healthcare institutions, and others. Hospital pharmacies segment dominates meningococcal vaccine market share, as it is primary vaccine administration, with trained medical staff and necessary cold-chain storage facilities. Hospital pharmacies offer administration of meningococcal vaccines under medical supervision, and manage patient care, is projected to segment’s growth in meningococcal vaccine market.

Regional Insights:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This region hold the largest share of 38.0% and expected to dominant region over the forecast period. A well-established healthcare structure and increase in awareness about meningococcal vaccine, which increases the adoption of vaccine, is anticipated to drive target market growth. Government are focusing on improving healthcare infrastructure and rising investment in vaccine production are anticipated to growth of meningococcal vaccine market in the region.

• U.S. Meningococcal Vaccine Market Insights:

The U.S, is the dominant country in North America region for meningococcal vaccine market. The U.S. has a well-established vaccination schedule that includes meningococcal vaccines for adolescents, significant travel population that requires meningococcal vaccination, ongoing public health initiatives and high awareness of meningococcal disease among healthcare professionals, is expected to growth of target market share.

Asia Pacific: This region is expected to grow at a significant rate during upcoming years. The increasing pediatric population and increasing prevalence of disease, is anticipated to target market growth. The rising healthcare improvements, and increasing healthcare awareness in countries such as China, Japan and India, are creating unique opportunities for treatment development, resulting to drive meningococcal vaccine market in upcoming years.

• Australia Meningococcal Vaccine Market Insights:

Australia hold the significant share in Asia Pacific region for meningococcal vaccine market. Australia has a highly developed public health system with strong immunization programs, including meningococcal vaccination for both infants and adolescents. The National Immunisation Program (NIP) in Australia has made significant strides in reducing the burden of meningococcal disease, is projected to growth of target market.

Europe: This region represents a significant market for meningococcal vaccines driven by a combination of high healthcare standards, routine immunization programs, and increasing awareness of meningococcal disease. Rising awareness about importance of preventive vaccines, and strong healthcare infrastructure, is expected to boost meningococcal vaccine market share.

• U.K. Meningococcal Vaccine Market Insights:

In meningococcal vaccine market U.K. is leading country for the Europe region. The National Health Service (NHS) in the U.K. plays a significant role in ensuring widespread access to vaccines, contributing to high vaccine coverage rates, ongoing health campaigns, educational efforts have raised awareness about importance of vaccination, is propel the expansion of meningococcal vaccine market.

Meningococcal Vaccine Market Report Scope:

Attribute	Details
Market Size 2025	USD 3.5 Billion
Projected Market Size 2035	USD 6.1 Billion
CAGR Growth Rate	6.3% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Billion & CAGR from 2025 to 2035
Regional scope	North America - U.S., and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India Japan, Australia Indonesia Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa – GCC, Israel South Africa, and Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Vaccine Type:

• Conjugative
• Polysaccharide
• Others

By Serotype:

• Serotype A
• Serotype B
• Serotype C
• Serotype W
• Serotype Y

By Age Group:

• Infants
• Children & Adults

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Healthcare Institutions
• Others

 By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Merck & Co., Inc., GSK plc, Pfizer Inc., and others are the key player’s operating in the meningococcal vaccine market. These key players are focusing on improving on research and development, aim to develop novel vaccine for meningococcal disease and expanding the application of existing vaccine in age groups, resulting to drive meningococcal vaccine market growth.  

Meningococcal Vaccine Market Companies:

• BIO-MED
• GSK plc.
• Pfizer Inc.
• Sanofi
• Merck & Co., Inc.
• Novartis AG
• CSL
• Johnson & Johnson Services, Inc.
• Bharat Biotech
• Serum Institute of India Pvt. Ltd.
• SINOVAC
• Biological E Limited
• Zhi Fei Biological
• Beijing Tiantan Biological Products Co., Ltd.
• Walvax Biotechnology Co., Ltd.
• DCVMN International

View an Additional List of Companies in the Meningococcal Vaccine Market

• In February 2025, GSK plc, received approval from FDA for Penmenvy meningococcal vaccine. This vaccine aimed to target five major serogroups of Neisseria meningitides such as, A, B, C, W, and Y, which cause invasive meningococcal disease (IMD). This vaccine aimed to improve meningococcal vaccination coverage especially for IMD caused by serogroup B.
• In April 2024, The World Health Organization introduced new meningococcal vaccine, known as Men5CV, for the public health in Africa, particularly in Nigeria. Men5CV provide protection against five strains of the Neisseria meningitides bacteria, of A, C, W, Y, and X. Men5CV represented as effective against meningitis diseases by offered protection against five most prevalent strain of meningococcal bacteria.
• In October 2023, Pfizer Inc., received approval from U.S. FDA for the PENBRAYA, a meningococcal groups A, B, C, W and Y vaccine. It was first and only prevalence vaccine that provides coverage against serogroups causing causing meningococcal disease in adolescents and young adults 10 through 25 years of age. PENBRAYA was the combination of two meningococcal vaccines, Trumenba and Nimenrix, aimed to protect against the five most common meningococcal serogroups that cause IMD globally.
• In July 2023, Serum Institute of India received World Health organization (WHO) prequalification, for multivalent meningococcal meningitis vaccine. MenFive was a multivalent conjugate vaccine designed to protect against the five major strains of meningococcal meningitis, which are the predominant causes of meningitis epidemics in sub-Saharan Africa. This prequalification allowed MenFive included in the global vaccine supply chain and purchased by international health organizations, such as the United Nations and Gavi, The Vaccine Alliance.
• In March 2023, GSK plc, announced positive results from the phase III trial of its MenABCWY combination vaccine in healthy individuals aged 10-25 years. GSK’s MenABCWY vaccine candidate was combination of the antigenic components of its licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY).

Analyst View:

The increasing incidence of meningococcal, rising awareness through global vaccination programs and introduction of newer vaccines, is anticipated to drive target market growth. The public health organization, such as WHO, GAVI and UNICEF, are focusing on development of advanced vaccines in rural areas, to reduce global burden. The increasing introduction of new vaccines to protect against multiple meningococcal serogroups, and rapidly approving these vaccine from regulatory bodies, is anticipated to drive meningococcal vaccine market growth.

More Related Reports

Foot and Mouth Disease Vaccine Market
Mono Vaccines (Epstein-Barr virus) Market
Vaccine Adjuvant Market
H1N1 Vaccine Market
Coronavirus Vaccine Market

Company Name	Merck & Co.
Headquarter	Kenilworth, New Jersey
CEO	Robert M. Davis
Employee Count (2024)	62,908 employees